Vantas FDA Approval History
FDA Approved: Yes (First approved October 12, 2004)
Brand name: Vantas
Generic name: histrelin
Dosage form: Implant
Company: Valera Pharmaceuticals
Treatment for: Prostate Cancer
Vantas (histrelin) implant is an LHRH agonist administered once-yearly for the palliative treatment of advanced prostate cancer.
Development timeline for Vantas
| Date | Article |
|---|---|
| Oct 12, 2004 | Approval Vantas Valera Pharmaceuticals - Treatment for Prostate Cancer |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
